PHARE* Trial results of subset analysis comparing 6 to 12 … · PHARE* Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer Protocol
Post on 27-Mar-2021
1 Views
Preview:
Transcript
PHARE* Trial results of subset
analysis comparing 6 to 12
months of trastuzumab in
adjuvant early breast cancer
Protocol of
Herceptin®
Adjuvant with
Reduced
Exposure
adjuvant early breast cancer
*lighthouse in French
Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat,
Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin,
Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie,
Nicole Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat,
Iris Pauporté, Andrew Kramar.
Disclosures
• Honoraria and Consultant for Roche, GlaxoSmithKline
• The PHARE trial is fully funded and conducted by the • The PHARE trial is fully funded and conducted by the
French National Cancer Institute (INCa)
Eligibility
• Non metastatic operable, histologically confirmed adenocarcinoma of the breast
• Axillary nodes positive or negative and tumor size ≥ 10 mm
• At least four cycles of a chemotherapy for this breast cancer
• Patients for whom a 12-month adjuvant treatment with trastuzumab has been initiated
X Pivot et al, ESMO 2012, LBA5_PR
trastuzumab has been initiated
• Baseline LVEF value 3 months after initiation of treatment with trastuzumab allowing to pursue treatment
• Overexpression of HER2 in invasive component of primary tumor
• Signed informed consent
• Patients with history of other cancer eligible
Study design
trastuzumab 6 months
trastuzumab up to 12 months
stop trastuzumab
RRStratification
1. ER pos / neg
2. Chemo: conco/ seq stop trastuzumab
Clinical examLVEF
3
Mammography
6 9 12 15 18 21 24 30 mos
…
0
R: Randomization after informed consent
Up to 60 mos…
2. Chemo: conco/ seq
Statistical Methods
• Non inferiority randomized trial
– 2% variation in terms of absolute difference of recurrence
– The 95% CI HR margins should not cross the 1.15 boundary
– 1040 DFS events required for 80% power at 5% level
oror
4 years of accrual and at least 2 years of follow-up
– HR were estimated from the stratified Cox model
• Accrual target: 3400 patients
Study informationActivated: 30/05/2006
4 patients excluded from analysis1 Informed consent not signed1 Randomized twice2 HER2 negative after FISH testing
Randomization3384 patients
Trastuzumab 12 months1690 patients
Trastuzumab 6 months1690 patients
•May 28th 2010 – IDMC meeting
“After careful thought and lengthy debate we recommend that entry to the trial be suspended.We do not recommend, at this time, a crossover to a longer duration of intervention for the 6 month group but would reserve the option of such a recommendation for the future, dependent on how the data develop”
Closed: 09/07/2010Database locked: 31/07/2012
Patient Characteristics12 monthsn=1690
6 monthsn=1690
Age, median (range) 54 (21 – 86) 55 (23 – 85)
Tumor: 0 – 2 cm2 – 5 cm>5 cm
54.7%38.5%6.8%
52.4%39.8%7.8%
Nodes: negative1 – 3 nodes
55.4%30.0%
54.7%30.2%1 – 3 nodes
≥4 nodes30.0%14.6%
30.2%15.1%
Positive Estrogen receptor 57.6% 58.8%
Inflammatory disease 3.5% 3.4%
SBR: IIIIII
3.1%41.0%55.6%
3.3%40.9%55.8%
Treatment Characteristics
12 monthsn=1690
6 monthsn=1690
Type of Chemotherapy No AnthracyclinesAnthracyclines no taxanesAnthracyclines and Taxanes
10.2%15.9%73.9%
11.8%15.5%72.7%
Concomitant ChemotherapySequential Chemotherapy
57.8%42.2%
57.7%42.3%Sequential Chemotherapy 42.2% 42.3%
Radiotherapy 87.7% 88.2%
Hormonotherapy 50.6% 50.2%
Trastuzumab duration, mean (sd) 11.8 (2.03) 6.3 (1.46)
DFS Events
12 mos(n=1690)
6 mos(n=1690)
DFS Events (n=394) 10.4% 13.0%
Local RecurrenceRegional Recurrence
1.1%0.6%
1.4%0.5%
42.5mos. median Follow-up
Regional RecurrenceDistant Recurrence
Controlateral Breast Cancer2nd Primary Malignancy
Death
0.6%6.4%
0.4%1.5%
0.4%
0.5%8.3%
0.7%1.5%
0.5%
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR (95% CI): 1.28 (1.05 - 1.56)
Disease Free Survival
95.5 91.2 87.8 84.9
97.0 93.8 90.7 87.8
Events HR 95%CI p-value
T 12m 176
0.00
0.25
DF
S P
rob
ab
ilit
y
1690 1586 1353 939 526 23T-6m
1690 1613 1390 980 544 18T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6m
* Cox model stratified by ER status and concomitant chemotherapy
T 12m 176
T 6m 219 1.28 (1.05 – 1.56) 0.29
Equivalent
Superior
A
B
Primary endpoint scenarios
Non Inferior
Inferior
C
D
E
.85 1 1.15 1.3 1.45 1.6
HR
PHARE trial
X Pivot et al, ESMO 2012, LBA5_PR
Subgroup effects
Objective and strategyof subgroup analysis
• The aim of this analysis was to assess the trastuzumab
duration effects for specific subgroups
– Identified by pre-defined stratification factors
• Estrogen receptor status• Estrogen receptor status
• Sequential or concomitant administration of trastuzumab with
chemotherapy
• Assess heterogeneity by interaction tests
– 0.10 significance level
Trastuzumab duration effect:according to ER
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.34 : 95%CI: (1.02 - 1.76), p=0.037
0.50
0.75
1.00
DFS
Pro
ba
bil
ity
HR = 1.23 : 95%CI: (0.92 - 1.65), p=0.15
ER negative ER positive
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
ER negative 92 716 0.888 117 696 0.829
ER positive 83 974 0.920 102 994 0.912
0.00
0.25
DF
S P
rob
ab
ilit
y
696 639 544 373 207 8T-6m
716 668 568 410 221 6T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER negative 0.00
0.25
DFS
Pro
ba
bil
ity
994 947 809 566 319 15T-6m
974 945 822 570 323 12T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER positive
Trastuzumab duration effect:Treatment modalities
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.15 : 95%CI: (0.88 - 1.53), p=0.32
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.41 : 95%CI: (1.06 - 1.86), p=0.016
Sequential Concomitant
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
Sequential 84 729 0.904 117 747 0.857
Concomitant 91 961 0.907 102 943 0.896
0.00
0.25
DF
S P
rob
ab
ilit
y
943 894 748 454 217 4T-6m
961 922 774 478 220 1T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mConcomitant0.00
0.25
DF
S P
rob
ab
ilit
y
747 692 605 485 309 19T-6m
729 691 616 502 324 17T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mSequential
Estrogen Receptorand Chemo-trastuzumab modalities
DFS Main effects model Nested Interaction model
N=3380 HR 95% CI P HR 95% CI P
ER + 0.61 (0.50 – 0.75) <0.0001 0.52 (0.39–0 .68) <0.0001
Conc 0.83 (0.68 – 1.01) 0.065 0.71 (0.54–0.93) 0.013
ER* Conc --- 1.41 (0.95–2.09) 0.093
• Significant interaction– * Reference category
LR test –3077.38 –3075.96 0.092
Sequential Concomitant
ER – HR* = 1.00 HR = 0.71(0.59 – 0.85)
ER + HR = 0.52(0.39 – 0.68)
HR = 0.51(0.39 – 0.67)
Sequential Concomitant
ER – HR* = 1.00 HR = 0.83(0.68 – 1.01)
ER + HR = 0.61(0.50 – 0.75)
HR = 0.51(0.38 – 0.67)
Trastuzumab duration effect:ER negative – Sequential modality
.006
Ha
zard
ra
te
0.25
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.57 : 95%CI: (1.08 - 2.28)
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
46 312 0.875 69 314 0.786
HR = 1.57 (1.08 – 2.28)
0
.002
.004
Ha
zard
ra
te
0 12 24 36 48 60Months
T-12m T-6mER neg - Sequential
0.00
0.25
314 282 244 188 113 8T-6m
312 288 254 210 130 5T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER neg - Sequential
Trastuzumab duration effect: ER negative – concomitant modality
.004
.006
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.10 : 95%CI: (0.73 -1.65)
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
46 404 0.898 48 382 0.866
HR = 1.10 (0.73 – 1.65)
0
.002
.004
Ha
zard
ra
te
0 12 24 36 48 60Months
T-12m T-6mER neg - Concomitant
0.00
0.25
382 357 300 185 94 0T-6m
404 380 314 200 91 1T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER neg - Concomitant
Trastuzumab duration effect: ER positive- Sequential modality
.004
.006
Ha
zard
ra
te
0.25
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.25 : 95%CI: (0.81 -1.91)
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
38 417 0.925 48 433 0.908
HR = 1.25 (0.81 – 1.91)
0
.002
Ha
zard
ra
te
0 12 24 36 48 60Months
T-12m T-6mER pos - Sequential
0.00
0.25
433 410 361 297 196 11T-6m
417 403 362 292 194 12T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER pos - Sequential
Trastuzumab duration effect: ER positive- concomitant modality
.004
.006
Ha
zard
ra
te
0.50
0.75
1.00
DF
S P
rob
ab
ilit
y
HR = 1.23 : 95%CI: (0.83 -1.82)
Trastuzumab 12 months Trastuzumab 6 months
Events N DFS-3 Events N DFS-3
45 557 0.913 54 561 0.916
HR = 1.23 (0.83 –1.82)
0
.002
Ha
zard
ra
te
0 12 24 36 48 60Months
T-12m T-6mER pos - Concomitant
0.00
0.25
561 537 448 269 123 4T-6m
557 542 460 278 129 0T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER pos - Concomitant
Conclusion
ER and Chemotherapy modalities
1.57 (1.08 - 2.28)
1.25 (0.81 - 1.91)
ER - Sequential (676)
ER + Sequential (850)
1.10 (0.73 - 1.65)
1.23 (0.83 - 1.82)
1.28 (1.05 - 1.56)
ER - Concomitant (786)
ER + Concomitant (1118)
All patients (3380)
0 1.15 2
Conclusion
• PHARE failed to show that 6 months of trastuzumab is non
inferior to 12 months
• Subgroups analysis suggested
– Sequential modality for ER negative tumors impacted the overall
results
– Results in other groups seemed compatible with non-inferiority
hypothesis
• PHARE longer FU & PERSEPHONE, SHORTHER & SOLD
trial results are expected
Acknowledgments
• All patients and their families
• The IDMC members
• French National Cancer Institute staff:
Céline Faure-Mercier, Nicolas Thammavong, Céline Faure-Mercier, Nicolas Thammavong,
Nadia Bachouche, Claire Verbeke
• Marc Buyse and Xavier Paoletti for their input in the
original trial design
www.clinicaltrials.gov: NCT00381901www.e-cancer.fr: essai Phare
All InvestigatorsACHILLE, ACHOUR, AGOSTINI, AL AUKLA, ALBIN, ALCARAZ, ALLEAUME, ALLIOT, ALTWEGG, AMSALHEM, ANDRE, ANTOINE,
ARDISSON, ARSENE, AUCLERC, AUDHUY, AULIARD, AVENIN, BARATS, BARBET, BATICLE, BAUMONT, BEERBLOCK, BEGUE, BEGUIER,
BELLAICHE – MICCIO, BERNARD, BERTON-RIGAUD, BESSON, BICHOFFE, BIELSA, BIRON, BONICHON-LAMICHHANE, BONNETERRE,
BONS, BOUE, BOUGNOUX, BOULANGER, BOURBOULOUX, BOURCIER, BOURGEOIS, BOUSQUET, BOUTAN –LAROZE, BRAIN, BRAIN,
BREAU, BRUNA, BURKI, CAILLEUX, CALS, CAMPONE, CAMPOS-GAZEAU, CAPITAIN, CAROLA, CARTRON, CAUVIN, CHAIGNEAU,
CHANTELARD, CHEVRIER, CHIEZE, CHIRAT, CHOLLET, CHOUAHNIA, CLAVREUL, CLIPPE, CLUET, COEFFIC, COJEAN-ZELEC, COLLARD,
COMBE, COSTA, COTTU, COUDERC, COUDERT, CRETIN, CURE, CUVIER, DALENC, DARLOY, DARUT-JOUVE, DAUBA, DE HARTINGH, DE
SAINT HILAIRE, DEBLED, DELALOGE, DELBALDO, DELECROIX, DELVA, DELZENNE, DEMARCHI, DENIS, DENIZON, DIAB, DIERAS,
DIETMANN, DILLIES, DION, DOHOLLOU, DOMAS, DOMONT, DRONY, DUFRESNE, DUJOLS, DUPUIS, DUPUY, DUPUY-BROUSSEAU,
DURAND, DURANDO, DURIEUX, DUTEL, DUVERT, EGRETEAU, EL AMARTI, EL KOURI, ELLIS, EXTRA, EYMARD, EZENFIS, FABBRO,
FACCHINI, FALANDRY, FEDERICO, FERRANT, FERRERO, FERRIERE, FICHET, FOLLANA, FREYER, FRIC, GABEZ, GALOTTE, GANEM,
GARNIER, GAUTIER-FELIZOT, GEAY, GEDOUIN, GENET, GHOUL, GIACCHETTI, GIRAUD, GIRRE, GLADIEFF, GLIGOROV, GOUBELY, GARNIER, GAUTIER-FELIZOT, GEAY, GEDOUIN, GENET, GHOUL, GIACCHETTI, GIRAUD, GIRRE, GLADIEFF, GLIGOROV, GOUBELY,
GOUDIER, GOUTTEBEL, GREGET, GRENIER, GROSSAT, GUASTALLA, GUARDIOLA, GUILLEMET, GUILLET, GUIMONT, GUINET,
GUTIERREZ, HAJJAJI, HARDY-BESSARD, HENRY, HERVE, HOCINI, HOUYAU, IBANEZ MARTIN, IURISCI, JACQUOT, JANSSEN, JAUBERT,
JOUVE, JOVENIN, KANOUI, KARA –SLIMANE, KIRSCHER, KREITMANN, LAGUERRE, LAHARIE- MINEUR, LAMY, LANCRY, LAPORTE,
LARGILLIER, LAUCHE, LAURENCE, LAVAU-DENES, LE HEURTEUR, LE MAIGNAN, LE ROL, LEBOUVIER SADOT, LEBRUN, LEDUC,
LEFEUVRE, LEGOUFFE, LEGUEUL, LEHEURTEUR, LEVACHE, LEVY, LEYRONNAS, L'HELGOUALC'H, LIGEZA-POISSON, LITOR, LLORY,
LOISEAU, LUPORSI, MADRANGES, MAHOUR BACHA, MAILLART, MANDET, MANGOLD, MARI, MARTI, MARTIN, MAURIAC, MAYER,
MAYEUR, MEDIONI, MEFTI- LACHERAF, MERAD-BOUDIA, MEUNIER, MEUNIER, MIGNOT, MILLE, MISSET, MONTCUQUET, MORAN
RIBON, MORICEAU, MORVAN, MOULLET, MOURET-REYNIER, MOUTEL-CORVIOLE, NABHOLTZ, NETTER, N'GUYEN, NOUYRIGAT,
ODDOU-LAGRANIERE, ORFEUVRE, PARAISO, PAVLOVITCH, PETIT, PIPERNO-NEUMANN, PIPROT, PLANTADE, PLAT, PORTOIS,
POTTIER-KYNDT, POUESSEL, POURNY, PRIOU, PROVENCAL, RABAN, RAICHON PATRU, RAMEE, RATOANINA, RAY-COQUARD, RE,
REBATTU, RIGAL, RIVERA, ROCHE, ROCHE FORESTIER, ROHART DE CORDOUE, ROUSSEAU, RUCK, SAAD, SADKI-BENAOUDIA,
SAINTIGNY, SALLES, SALVAT, SARDA, SARRAZIN, SCHAEFFER, SERVENT, SEVIN –ROBICHE, SLAMA, SOULIE, SOYER, SPIELMANN,
STEFANI, STEIN, TADRIST, TARPIN, TARTAS, TEISSIER, TENNEVET, THEVENOT, TOCCANIER, TOURNIGAND, TRAGER-MAURY,
TREDAN, TRESCA, TRILLET-LENOIR, UWER, VALENZA, VAN PRAAGH, VAN-HULST, VANICA, VANLEMMENS, VANNETZEL, VANNEUVILLE,
VANOLI, VAULEON, VEDRINE, VENNIN, VEYRET, VIGNOT, VIGNOUD, VILLANUEVA, VILLING, VINCENT, VOLOCH, WEBER, YAKENDJI,
YAZBEK, YOUSSEF, ZYLBERAIT
BACK UP
Conclusion
0.75
1.00
DF
S P
rob
ab
ilit
y
0.75
1.00
Trastuzumab duration effect: subgroup other patients
Trastuzumab duration effect: subgroup ER negative – Sequential
modality
0.00
0.25
0.50
DF
S P
rob
ab
ilit
y
314 282 244 188 113 8T-6m
312 288 254 210 130 5T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mER neg - Sequential
HR = 1.57 : 95%CI: (1.08 - 2.28)
0.00
0.25
0.50
DF
S P
rob
ab
ilit
y1376 1304 1109 751 413 15T-6m
1378 1325 1136 770 414 13T-12m
Trastuzumab
0 12 24 36 48 60Months
T-12m T-6mOther groups
HR = 1.18 : 95%CI: (0.93 -1.49)
top related